OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone574-268-6379
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$57.56 million
Profitability
Miscellaneous
Employees80
Next Earnings Date10/30/2019 (Estimated)
OptionableNot Optionable
Orthopediatrics (NASDAQ:KIDS) Frequently Asked Questions
What is Orthopediatrics' stock symbol?
Orthopediatrics trades on the NASDAQ under the ticker symbol "KIDS."
How were Orthopediatrics' earnings last quarter?
Orthopediatrics Corp (NASDAQ:KIDS) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.05. The business earned $18.20 million during the quarter, compared to analysts' expectations of $18.44 million. Orthopediatrics had a negative net margin of 15.77% and a negative return on equity of 12.92%. The firm's quarterly revenue was up 20.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.21) earnings per share. View Orthopediatrics' Earnings History.
When is Orthopediatrics' next earnings date?
What price target have analysts set for KIDS?
3 Wall Street analysts have issued twelve-month price objectives for Orthopediatrics' shares. Their predictions range from $44.00 to $53.00. On average, they anticipate Orthopediatrics' stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price. View Analyst Price Targets for Orthopediatrics.
What is the consensus analysts' recommendation for Orthopediatrics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orthopediatrics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orthopediatrics.
What are Wall Street analysts saying about Orthopediatrics stock?
Here are some recent quotes from research analysts about Orthopediatrics stock:
- 1. According to Zacks Investment Research, "OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. " (10/10/2019)
- 2. BTIG Research analysts commented, "We maintain our Buy rating and $44 PT following 1Q19 results which saw softer than anticipated Trauma & Deformity sales resulting from weakness in elective deformity procedures. Overall rev. was in-line with BTIG/Street estimates of $14.8M/$14.7M as continued strength in Scoliosis offset T&D softness (~$900k estimated). Despite the 1Q weakness, mgmt. noted that KIDS had not lost share nor seen competitive encroachment and that deformity procedure volumes have come back noticeably in 2Q to date. That said, at KIDS’ multiple we feel shares will be pressured at least until the bounce-back in volume is seen in 2Q. We continue to view a significant market opportunity, a robust pipeline (both organically and inorganically), and limited competition as able to support continued 20%+ growth (here)." (5/10/2019)
Has Orthopediatrics been receiving favorable news coverage?
Press coverage about KIDS stock has trended somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Orthopediatrics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Orthopediatrics.
Are investors shorting Orthopediatrics?
Orthopediatrics saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,070,000 shares, an increase of 5.9% from the August 30th total of 1,010,000 shares. Based on an average trading volume of 85,300 shares, the short-interest ratio is currently 12.5 days. Approximately 12.1% of the company's stock are sold short. View Orthopediatrics' Current Options Chain.
Who are some of Orthopediatrics' key competitors?
Some companies that are related to Orthopediatrics include Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Cardiovascular Systems (CSII), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC), Silk Road Medical (SILK), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Luminex (LMNX), Cryolife (CRY), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT) and Cerus (CERS).
What other stocks do shareholders of Orthopediatrics own?
Who are Orthopediatrics' key executives?
Orthopediatrics' management team includes the folowing people:
- Mr. Mark C. Throdahl, Pres, CEO & Director (Age 68)
- Mr. Fred L. Hite, CFO & Director (Age 51)
- Mr. Daniel J. Gerritzen, VP of Legal & HR, Gen. Counsel and Sec. (Age 49)
- Mr. David R. Bailey, Exec. VP (Age 40)
- Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 49)
When did Orthopediatrics IPO?
(KIDS) raised $52 million in an initial public offering (IPO) on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.
Who are Orthopediatrics' major shareholders?
Orthopediatrics' stock is owned by many different of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (3.43%), Roubaix Capital LLC (0.81%) and Envestnet Asset Management Inc. (0.05%). Company insiders that own Orthopediatrics stock include Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite and Kevin Unger. View Institutional Ownership Trends for Orthopediatrics.
Which major investors are buying Orthopediatrics stock?
How do I buy shares of Orthopediatrics?
Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Orthopediatrics' stock price today?
One share of KIDS stock can currently be purchased for approximately $36.18.
How big of a company is Orthopediatrics?
Orthopediatrics has a market capitalization of $540.53 million and generates $57.56 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Orthopediatrics employs 80 workers across the globe.View Additional Information About Orthopediatrics.
What is Orthopediatrics' official website?
How can I contact Orthopediatrics?
Orthopediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at 574-268-6379 or via email at [email protected]
MarketBeat Community Rating for Orthopediatrics (NASDAQ KIDS)
MarketBeat's community ratings are surveys of what our community members think about Orthopediatrics and other stocks. Vote "Outperform" if you believe KIDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
